| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2602 | 2019 |
| Diabetes and cognitive dysfunction RJ McCrimmon, CM Ryan, BM Frier The Lancet, 2012 | 1090 | 2012 |
| Exercise management in type 1 diabetes: a consensus statement MC Riddell, IW Gallen, CE Smart, CE Taplin, P Adolfsson, AN Lumb, ... The lancet Diabetes & endocrinology 5 (5), 377-390, 2017 | 933 | 2017 |
| Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the … SA Amiel, P Aschner, B Childs, P Cryer, B de Galan, SA Heller, BM Frier, ... Diabetologia, 2016 | 750* | 2016 |
| Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010 SJ Livingstone, D Levin, HC Looker, RS Lindsay, SH Wild, N Joss, ... Jama 313 (1), 37-44, 2015 | 725 | 2015 |
| Frequency of thyroid dysfunction in diabetic patients: value of annual screening P Perros, RJ McCrimmon, G Shaw, BM Frier Diabetic medicine 12 (7), 622-627, 1995 | 712 | 1995 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138, 2019 | 601 | 2019 |
| Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance EC McNay, CT Ong, RJ McCrimmon, J Cresswell, JS Bogan, RS Sherwin Neurobiology of learning and memory 93 (4), 546-553, 2010 | 470 | 2010 |
| Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management SA Amiel, P Aschner, B Childs, PE Cryer, BE de Galan, BM Frier, ... The lancet Diabetes & endocrinology 7 (5), 385-396, 2019 | 444 | 2019 |
| Synaptic glutamate release by ventromedial hypothalamic neurons is part of the neurocircuitry that prevents hypoglycemia Q Tong, CP Ye, RJ McCrimmon, H Dhillon, B Choi, MD Kramer, J Yu, ... Cell metabolism 5 (5), 383-393, 2007 | 438 | 2007 |
| Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia SC Ferguson, A Blane, P Perros, RJ McCrimmon, JJK Best, J Wardlaw, ... Diabetes 52 (1), 149-156, 2003 | 374 | 2003 |
| Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland SJ McGurnaghan, A Weir, J Bishop, S Kennedy, LAK Blackbourn, ... The lancet Diabetes & endocrinology 9 (2), 82-93, 2021 | 361 | 2021 |
| Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function SC Ferguson, A Blane, J Wardlaw, BM Frier, P Perros, RJ McCrimmon, ... Diabetes Care 28 (6), 1431-1437, 2005 | 325 | 2005 |
| Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised … P Dandona, C Mathieu, M Phillip, L Hansen, SC Griffen, D Tschöpe, ... The lancet Diabetes & endocrinology 5 (11), 864-876, 2017 | 315 | 2017 |
| Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways L Zhou, GM Sutton, JJ Rochford, RK Semple, DD Lam, LJ Oksanen, ... Cell metabolism 6 (5), 398-405, 2007 | 275 | 2007 |
| Hypoglycemia in type 1 diabetes RJ McCrimmon, RS Sherwin Diabetes 59 (10), 2333-2339, 2010 | 270 | 2010 |
| Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein … PJ Meakin, S Chowdhry, RS Sharma, FB Ashford, SV Walsh, ... Molecular and cellular biology 34 (17), 3305-3320, 2014 | 251 | 2014 |
| Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b … I Lingvay, AM Catarig, JP Frias, H Kumar, NL Lausvig, CW le Roux, ... The lancet Diabetes & endocrinology 7 (11), 834-844, 2019 | 243 | 2019 |
| Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study P Dandona, C Mathieu, M Phillip, L Hansen, D Tschöpe, F Thorén, J Xu, ... Diabetes Care 41 (12), 2552-2559, 2018 | 233 | 2018 |
| Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial NA Mordi, IR Mordi, JS Singh, RJ McCrimmon, AD Struthers, CC Lang Circulation 142 (18), 1713-1724, 2020 | 211 | 2020 |
Mark EvansUniversity of Cambridge在 cam.ac.uk 的电子邮件经过验证
